Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Free Cash Flow (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Free Cash Flow for 2 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 85.22% to -$2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2025, up 70.08% year-over-year, with the annual reading at -$5.5 million for FY2025, 70.08% up from the prior year.
  • Free Cash Flow hit -$2.1 million in Q4 2025 for Xilio Therapeutics, up from -$17.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $29.0 million in Q1 2025 to a low of -$17.5 million in Q3 2025.